• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tectonic Therapeutic Inc.

    7/1/24 4:39:28 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email
    SC 13G 1 tecx13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

    Tectonic Therapeutic, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    878972108

    (CUSIP Number)

    June 20, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 878972108

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 849,143
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 849,143

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 849,143

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.8%

     

    12.Type of Reporting Person (See Instructions) OO, IA

     2 
    CUSIP No. 878972108

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 849,143
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 849,143

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 849,143

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.8%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

     3 
    CUSIP No. 878972108

     

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power -0-

     

    6. Shared Voting Power 783,214
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 783,214

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 783,214

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     4 
    CUSIP No. 878972108

     

    Item1.
    (a)Name of Issuer

    Tectonic Therapeutic, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    490 Arsenal Way, Suite 210, Watertown, MA 02472

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, par value $0.0001 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 878972108.
     5 
    CUSIP No. 878972108

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 14,734,323 shares of Common Stock outstanding as June 20, 2024, as reported in the Form 8-K filed by the Issuer on June 20, 2024.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of EcoR1 and Mr. Nodelman:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Qualified Fund:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     6 
    CUSIP No. 878972108

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 1, 2024

     

    EcoR1 CAPITAL, LLC

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
     7 
    CUSIP No. 878972108

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: July 1, 2024

    EcoR1 CAPITAL, LLC

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

    Get the next $TECX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    6/24/2024Buy
    TD Cowen
    More analyst ratings

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/11/25 6:12:08 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/9/25 5:38:10 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mcguire Terrance sold $8,550,000 worth of shares (500,000 units at $17.10) (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/7/25 5:02:43 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/11/25 6:12:08 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/9/25 5:38:10 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $39,999,977 worth of shares (789,294 units at $50.68), increasing direct ownership by 3% to 4,226,058 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      2/7/25 4:21:19 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

      Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 daysTX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions ("LVEF"), including LVEF≥50% and LVEF 41-49% WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic") today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in pat

      5/17/25 10:40:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

      Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF")Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results expected in the second half of 2025Ongoing TX45 APEX Phase 2 trial continues to enroll with topline results expected in 2026Cash and cash equivalents were $306.2 million as of March 31, 2025, including

      5/8/25 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference

      WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care Conference Date:Thursday, May 15th, 2025Time:9:20am PDTFormat:Corporate PresentationPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link The

      5/7/25 8:00:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

      SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      5/15/25 2:24:51 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

      SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      5/12/25 10:43:30 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Tectonic Therapeutic Inc.

      424B3 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      5/8/25 4:33:19 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TECX
    Financials

    Live finance-specific insights

    See more
    • Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

      SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      11/14/24 4:05:11 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

      SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      10/28/24 6:08:43 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

      SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      10/24/24 5:12:09 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

      TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

      1/30/25 6:30:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

      Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

      11/7/24 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

      TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

      8/14/24 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Tectonic Therapeutic with a new price target

      Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00

      4/21/25 8:39:06 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Tectonic Therapeutic with a new price target

      Raymond James initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $65.00

      11/20/24 7:46:41 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on Tectonic Therapeutic with a new price target

      Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00

      8/22/24 7:34:40 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care